Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Certificate under 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.09.2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited's credit rating has been downgraded by CARE Ratings Limited due to a reduction in the scale of operations, significant deterioration in profitability margins, and weak debt coverage indicators.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has announced the results of its 45th Annual General Meeting (AGM), where all resolutions were passed with significant majority. The company has also declared a dividend for the financial year ended 31st March, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has submitted the Scrutinizer's report and voting results of its 45th Annual General Meeting (AGM) held on September 30, 2026. The company has informed the Exchange regarding voting results on four resolutions, including the appointment of a Director, declaration of dividend, and ratification of Remuneration of Cost Auditor.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has held its 45th Annual General Meeting, where the company's financial statements for the year ended 31st March 2026 were adopted, and various resolutions were passed, including the appointment of a director, declaration of dividend, and approval of loan and guarantee from promoters.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, including approval of dividend, raising funds through preferential issue, and amendment to Articles of Association.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Outcome of Annual General Meeting held on September 30, 2026, where the company's financial statements for the year ended March 31, 2026, were adopted, and various resolutions were passed, including the appointment of a director, declaration of dividend, and approval for loan and guarantee from promoters.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026. The meeting concluded with the approval of various resolutions, including the appointment of a director, declaration of dividend, and ratification of remuneration of cost auditor.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed from 1st October 2026 and will re-open after 48 hours from the declaration of un-audited financial results for the quarter and half year ending 30th September 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about a copy of newspaper publication for a corrigendum to the notice of its 45th Annual General Meeting.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has issued a corrigendum to the notice of its 45th Annual General Meeting, amending Resolution No. 8 and its explanatory statement to align with SEBI ICDR Regulations.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has announced the record date for the final dividend for FY 2025-26, to be paid after approval at the 45th Annual General Meeting on September 30, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has completed the acquisition of MicroBiopharm Japan Co., Ltd. through its wholly owned subsidiary, Themis Biosyn Japan Limited, for a total consideration of JPY 21.5 billion. The acquisition is expected to be EPS accretive and will accelerate GTBL's transition towards becoming a fermentation-based, globally integrated CDMO.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about the allotment of Non-Convertible Debentures (NCDs) aggregating INR 585 Crores on private placement basis. The Company is utilizing the NCDs proceeds inter alia for investing in its wholly subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd, and general corporate purpose.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Outcome of Board Meeting held on September 10, 2026, where the Board of Directors approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to INR 585 Crores on private placement basis.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has issued an addendum to the notice of its 45th Annual General Meeting (AGM) scheduled to be held on September 30, 2026. The addendum includes a special resolution to amend Article 119 of the company's Articles of Association, which deals with the right of a Financial Institution to appoint a Nominee Director on the Board of the Company.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication of 45th AGM notice.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Notice of 45th AGM to be held on September 30, 2026, to transact Ordinary and Special Businesses.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Outcome of Board Meeting held on September 01, 2026, where the Board of Directors approved the issuance of up to 82,10,786 fully paid-up equity shares of the Company of face value of Rs. 1 each at an issue price of Rs. 408/- per equity share, aggregating up to Rs. 335,00,00,688/-, to the proposed allottees, as detailed in Annexure A, by way of a preferential issue on a private placement basis.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Outcome of Committee Meeting held on August 28, 2026 for allotment of 2,11,86,440 Equity Shares to eligible QIBs at the issue price of Rs. 354 per Equity Share, aggregating to Rs. 749,99,99,760.